These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22492843)

  • 1. Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
    Nishii M; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Androl; 2012; 33(6):1233-8. PubMed ID: 22492843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    BMC Urol; 2017 Aug; 17(1):70. PubMed ID: 28851333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
    Zang T; Taplin ME; Tamae D; Xie W; Mesaros C; Zhang Z; Bubley G; Montgomery B; Balk SP; Mostaghel EA; Blair IA; Penning TM
    Endocr Relat Cancer; 2017 Aug; 24(8):393-404. PubMed ID: 28663228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
    Nakazato H; Suzuki K; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):6-12. PubMed ID: 11235144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
    Geller J
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
    van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
    J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels.
    Okamoto K; Sekine Y; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Basic Clin Androl; 2015; 25():3. PubMed ID: 28435682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
    Bélanger A; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.
    Morote J; Comas I; Ferrer R; Planas J; Celma A; Regis L
    J Biomed Sci; 2017 Oct; 24(1):81. PubMed ID: 29058606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
    Kawamura K
    Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.